A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
Status:
Recruiting
Trial end date:
2027-06-21
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of
combination of JNJ-87189401 with JNJ-78278343 (Part 1: dose escalation) and further evaluate
the safety at RP2Rs (Part 2: dose expansion) in participants with advanced prostate cancer.